You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201541 - 201550 of 207728 results
  1. Hetero-dimerization-activated Antibodies

    SBC: Panorama Research Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): The targets of most therapeutic antibodies are found on healthy cells which limits the development of truly tumor-specific therapies and results in a narrow therapeutic index. Using state-of-the-art proteomic and geneprofiling methods, our collaborators have identified unique sets of tumor-specific cell surface antigens that are not usually co-expressed on non ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) s

    SBC: Caladrius Biosciences            Topic: NIAID

    DESCRIPTION (provided by applicant): In the event of a nuclear accident or terrorist bomb, large numbers of casualties will have been exposed to acute high-dose radiation. Those exposed will have compromised immune systems such that the virulence and infectivity of biological agents is dramatically increased. A compromised immune system exacerbates the effects of infectious agents and may preclu ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Compounds to treat Helicobacter pylori infection

    SBC: ARIETIS CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to discover lead compounds acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Roughly every other person carries the pathogen, and there are an estimated 1.5 million cases annually of active infection in the US. The currently-used triple therapy is a combination of a proton pum ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. FGF-P to treat post-irradiation GI syndrome

    SBC: DiaCarta, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): For victims of gastrointestinal (GI) radiation exposure and concomitant GI syndrome, DiaCarta's fibroblast growth factor-peptide (FGF-P) is a product that will not only reduce depopulation and improve reepithelialization of the small bowel but also support bone marrow function. It could be the crucial factor that prevents mortality from GI syndrome. Our p ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Real-Time Reagent-Free Noninvasive Diagnosis of Tuberculosis

    SBC: Livermore Instruments Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite the human cost of tuberculosis (TB), the disease remains difficult to diagnose and thus to control. One-third of the world's population is infected with M. tuberculosis. Every year, more than 9 million people develop active TB and 1.7 million people die from the disease [WHO 2010]. Current widely used diagnostics perform poorly in identifying activ ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Low-cost, rapid quantitative Isothermal Assay for HIV RNA using ZNA

    SBC: BIOHELIX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): In this Phase I project, we propose to investigate a novel primer chemistry and probe detection system called the Zip nucleic acids (ZNA ). ZNAs are oligonucleotides conjugated to a number of cationic spermine moietiesthat enhance the effective concentration of primers and probes near nucleic acid targets. This property has been reported to enhance the speed ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Intravaginal ring delivery of tenofovir and emtricitabine

    SBC: AURITEC PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The long term goal of this project is to prevent HIV transmission. Using the drug delivery platform we developed for the ganciclovir intraocular implant, the Vitrasert(R), we propose to develop an intra-vaginal ring microbicide formulation releasing the antiretroviral agents tenofovir and emcitritabine. This drug combination has been chosen for potency, synergi ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Designing HIV Protease Inhibitors with Lower Dosing Requirements and Lower Toxici

    SBC: Amplyx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Optimizing HIV Protease Inhibitor Safety and Efficacy via Intracellular Targeting Abstract The AIDS epidemic is a global crisis with 31 million people worldwide who are living with HIV. According to the World Health Organization's 2010 revision of antiretroviral treatment therapy guidelines, creating less toxic therapies is a top priority to reduce adverse ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Point-of-care detection for nanoparticle-based sensors

    SBC: JUNCO LABS, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Although nanomaterials have tremendous potential to improve human health, it has remained surprisingly elusive to leverage their properties to produce real clinical impact. One of the most promising applications of nanoparticles is in sensors for detection of analytes. For sensors that need to be performed at the point of care (POC), one large barrier to unlock ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Hsp90 inhibitors to combat antifungal drug resistance.

    SBC: LIFEPHARMS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Fungal infections continue to be a major cause of morbidity and mortality among HIV-infected patients. Many of the emerging fungal pathogens that are resistant to the three classes of antifungal agents for AID-s-relatedinfections are becoming more common and are associated with higher rates of mortality. Combating drug resistant fungal pathogens should be a top ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government